# Age-related Macular Degeneration (AMD) Integrative Biology Initiative: Discovery of AMD Pathobiology using Patient-Derived Induced Pluripotent Stem Cell (iPSC)-derived Retinal Pigment Epithelium (RPE) (U01 Clinical Trial Not Allowed)

Source: https://welltoldgrants.com/grants/rfa-ey-21-002-age-related-macular-degeneration-amd-integrative-biology/  
Official notice: https://www.grants.gov/search-results-detail/336578

> National Institutes of Health offered grants of up to $250,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on February 17, 2022.

| Field | Value |
|---|---|
| Opportunity number | RFA-EY-21-002 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | February 17, 2022 |
| Award ceiling | $250,000 |
| Award floor | not stated |
| Expected awards | not stated |
| Total funding | not stated |
| Cost sharing | not required |
| Assistance Listings | 93.867 |

## Who can apply

- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

## What the grant funds

This Funding Opportunity Announcement (FOA) aims to support collaborative studies of a unique resource of patient-derived induced pluripotent stem cell (iPSC) lines generated by the NEI age-related macular degeneration (AMD) Integrative Biology Initiative. This resource also includes clinical, genomic, and imaging data from the patients from which these cells were derived, and a set of isogenic control cell lines in which the risk allele(s) have been corrected. These cell lines and clinical data are from patients with AMD carrying high prevalence risk alleles selected from the Age-Related Eye Disease Study 2 (AREDS2). The goal of this FOA is to determine if these iPSC-derived cell lines can be used to discover the underlying pathophysiology of AMD. Collaborative effort is highly encouraged with investigators bringing in the needed areas of expertise for successful projects.

## Questions people ask

### Is RFA-EY-21-002 still open?

No. It closed on February 17, 2022.

### Who can apply for Age-related Macular Degeneration (AMD) Integrative Biology Initiative: Discovery of AMD Pathobiology using Patient-Derived Induced Pluripotent Stem Cell (iPSC)-derived Retinal Pigment Epithelium (RPE) (U01 Clinical Trial Not Allowed)?

National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Age-related Macular Degeneration (AMD) Integrative Biology Initiative: Discovery of AMD Pathobiology using Patient-Derived Induced Pluripotent Stem Cell (iPSC)-derived Retinal Pigment Epithelium (RPE) (U01 Clinical Trial Not Allowed)?

Closed February 17, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

Awards of up to $250,000 each.

### Who has been funded under RFA-EY-21-002?

NIH RePORTER lists 4 projects funded under RFA-EY-21-002 in fiscal 2022 to 2024, at 4 institutions. The most were at Columbia University Health Sciences, Doheny Eye Institute, University of Washington.

### Who has won Vision Research grants before?

The largest recipients over five fiscal years were The Johns Hopkins University, The Leland Stanford Junior University, The Regents of the University of California, San Francisco. The program made 3,275 awards worth $3.4 billion in that time.